Y-mAbs Therapeutics, Inc.
YMAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 3.4% | 30% | 87% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 82.6% | 86.5% | 88.4% | 92.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -35% | -29.4% | -145.1% | -156.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -33.8% | -25.3% | -146.4% | -158.4% |
| EPS Diluted | -0.67 | -0.49 | -2.2 | -1.28 |
| % Growth | -36.7% | 77.7% | -71.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |